[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618621":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":30,"locations":11,"responsibleParty":40,"collaborators":11,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":11,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":11,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":11},{"fullName":5,"class":6},"Sisli Hamidiye Etfal Training and Research Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Group","EXPERIMENTAL",null,[13],"Procedure: Neural Therapy of Huneke",{"label":15,"type":16,"description":11,"interventionNames":17},"Control Group","ACTIVE_COMPARATOR",[18],"Drug: Betahistine 24 mg bid (Betaserc)",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"PROCEDURE","Neural Therapy of Huneke","The aim for tinnitus and facial pain is to regulate the trigeminal system and autonomic balance.\n\nConcentration used: Lidocaine 0.5%.\n\nThe auriculotemporal, infraorbital, zygomaticotemporal, and stellate regions were targeted.\n\nPuncture applications: 0.3-0.5 mL will be administered behind the ear, around the mastoid process, behind the tragus, and in the temporomandibular region.\n\nIf necessary, the stellate ganglion area can be supplemented with regulation injections.\n\nNegative aspiration and aseptic technique will be applied before each application.\n\nTransient mild dizziness or local redness may occur after application.\n\nTo avoid the risk of systemic toxicity, the total dose should generally not exceed a maximum of 200 mg of lidocaine.",[9],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"DRUG","Betahistine 24 mg bid (Betaserc)","Patients will be given Betahistine 16-48 mg\u002Fday in divided doses, depending on their weight and disease severity.",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":11,"email":35},"Roza Jizel Dağdelen, MD","CONTACT","+90 212 373 50 00","rozadagdelen@gmail.com",{"name":37,"role":33,"phone":38,"phoneExt":11,"email":39},"Jülide Öncü Alptekin, Professor Doctor, MD","+90507 231 6817","julideoncu@yahoo.com",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Roza Jizel Dagdelen MD","Medical Doctor , Assistant Researcher","100618621","the-effects-of-conventional-therapy-on-tinnitus-disability-and-quality-of-life-in-patients-with-tinnitus-100618621",false,"NCT07334002","The Effects of Conventional Therapy on Tinnitus, Disability, and Quality of Life in Patients With Tinnitus","A Randomized, Single-blind, Controlled Trial to Evaluate the Effects of Conventional Therapy on Tinnitus, Disability, and Quality of Life in Patients With Tinnitus","Inclusion Criteria:\n\n* Patients with a type A tympanogram in the tympanogram of all cases with normal otological examinations (air-bone gap should not be observed in any case).\n\nExclusion Criteria:\n\n* Patients with a disease that may cause objective tinnitus,\n\n  * Otosclerosis,\n  * Chronic otitis media,\n  * Acoustic tumor,\n  * Meniere's disease,\n  * History of ear surgery or head trauma, and those with neuropsychiatric diseases.\n\nAlso:\n\n* Patients who have had ear surgery,\n* Permanent hearing loss (total),\n* Severe cardiovascular system failure, uncontrolled arrhythmia,\n* Severe renal failure, or liver failure","ALL","18 Years","70 Years",{"count":55,"type":56},30,"ESTIMATED","INTERVENTIONAL",[59],"NA","A randomized, single-blind, controlled trial to evaluate the effects of neural therapy on tinnitus severity, disability, and quality of life in patients with tinnitus.\n\nThe study is planned to be conducted between December 2025 and March 2026. The sample size is 30 patients. The number of centers is 1. The study duration is 3 months.",[62,22],"Tinnitus",[22,62],"NOT_YET_RECRUITING","2026-03-20",{"date":67,"type":68},"2026-03-23","ACTUAL",{"date":70,"type":56},"2026-03-01",{"date":72,"type":56},"2026-05-26",{"name":5,"class":6}]